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Abstract 
Review on MIR296, with data on DNA/RNA and 
where the gene is implicated. 
Identity 
Other names: MIRN296, miRNA296 
HGNC (Hugo): MIR296 
Location: 20q13.32 
Local order: Orientation: minus strand. 
Based on Mapviewer, genes flanking miR296 on  
20q13.32 are: miR296; miR298; GNAS-AS1, GNAS 
antisense RNA 1; GNAS, GNAS complex locus. 
Note: miR296 has been implicated in cancerogenesis 
and it has been reported both over-expressed and lost in 
different human cancer cell types, suggesting that it 
functions as an oncogene or an oncosuppressor in 
different biological settings.  
Furthermore, miR296 has been also described to 
contribute to carcinogenesis by dysregulating p53. 
miR296 has been named an "angiomiR" because of its 
role in angiogenesis. 
 
 
Schematic representation of human chromosome 20 with highlight of miR296 locus (red dash). 
 
 
 
Stem-loop structure of miR-296, with mature miR-296-3p and miR-296-5p sequences highlighted in red. 
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miR-296 plays important roles in different cell types 
and cellular pathways, regulating several distinct 
mRNAs. 
Recently, miR-296, along with miR-298, has been 
demonstrated to be part of the GNAS complex locus, a 
highly complex cluster with imprinted gene expression, 
coding a stimulatory G-protein alpha subunit (Gs-α), 
involved in many signal transduction pathways 
(Robson et al., 2012). 
miR-296 was initially found to be specifically 
expressed in differentiated mouse embryonic stem 
cells, directly cross-talking with Nanog, Oct4 and Sox2 
gene (Houbaviy et al., 2003).  
It was also characterized in human embryonic stem 
cells (Suh et al., 2004; Lakshmipathy et al., 2007). 
miR-296 has been involved in antiviral responses 
induced by IFNα/IFNβ, inhibiting HCV replication 
directly targeting viral transcripts (Pedersen et al., 
2007). 
In a large series of human cancer cell lines and 
carcinoma specimens, miR-296 was identified as a 
comprehensive regulator of cell tumorigenicity, 
migration and invasion by inhibition of the expression 
of one of its targets, Scrib, a cytoplasmic protein that 
participates in multiprotein complexes (Vaira et al., 
2012). 
DNA/RNA 
Note 
Accession: NR_029844 
Description 
Size: 80 bases. 
Sequence: >gi|262206120|ref|NR_029844.1| Homo 
sapiens microRNA 296 (MIR296), microRNA. 
AGGACCCTTCCAGAGGGCCCCCCCTCAATCCT
GTTGTGCCTAATTCAGAGGGTTGGGTGGAGGC
TCTCCT GAAGGGCTCT. 
Transcription 
Pre-miR296: 
Accession: MI0000747 
Sequence: 
AGGACCCUUCCAGAGGGCCCCCCCUCAAUCCU
GUUGUGCCUAAUUCAGAGGGUUGGGUGGAGG
CUCUCCUGAAGGGCUCU 
Mature sequence hsa-miR296-5p 
Accession: MIMAT0000690 
Lenght: 21 nt 
Sequence: 14-agggcccccccucaauccugu-34 
Mature sequence hsa-miR296-3p 
Accession: MIMAT0004679 
Lenght: 22 nt 
Sequence: 48-gaggguuggguggaggcucucc-69 
 
 
 
 
Mutations 
 
Note 
SNP ID: rs117258475 
Position: chr20:57392686 
SNP Loc relative to pre-miR: 64 
Ref-allele: C/U 
Implicated in 
Various cancers 
Note 
miR-296 is variably expressed in different human 
cancers, it has been shown to be reduced or over-
expressed and to correlate with metastatic disease. 
miR-296 has an inhibitory function on different targets. 
Lung carcinomas 
Note 
In lung carcinomas, miR-296 is a tumour-suppressive 
miR as it has been found to be lost.  
The loss results in a repression of Numbl expression. 
Numbl becomes overexpressed and mislocalized in 
cancer cells from a variety of human tumors (Vaira et 
al., 2013). 
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Hepatocellular carcinomas 
Note 
miR-296 is lost during hepatocellular carcinomas 
progression. The loss of miR-296 deregulates cell 
polarity and plasticity. The resulting effect is an over-
expression of Scrib. miR296 regulates cell migration, 
invasion, and tumorigenicity, through the 
transcriptional repression of Scrib. miR296 or Scrib 
levels predict tumor relapse in hepatocellular 
carcinoma patients (Vaira et al., 2012). 
Prostate cancers 
Note 
miR-296 is a specific regulator of the oncogene 
HMGA1 in prostate cancer cells and is associated with 
prostate cancer growth and invasion. In this type of 
cancer there is an inverse correlation between HMGA1 
and miR-296 expression levels, and low miR-296 
expression levels correlate with advanced tumor grade 
and stage (Wei et al., 2011). 
Parathyroid carcinomas 
Note 
miR-296 has been found to be down-regulated in 
parathyroid carcinomas compared to normal 
parathyroid glands. miR-296 expression levels 
negatively correlated with hepatocyte growth factor 
receptor-regulated tyrosine kinase substrate mRNA 
expression levels. miR-296 might have a role as an 
oncosuppressor gene in these type of neoplasia 
(Corbetta et al., 2009). 
Esophageal carcinomas 
Note 
In squamous cell carcinomas of the esophagus, miR-
296 is reported to be over-expressed and to have a pro-
tumorigenic role. High levels of miR-296 are 
associated with resistance to chemotherapy, while its 
forced down-regulation resulted in increased sensitivity 
to standard chemotherapeutic agents and in decreased 
tumorigenesis of esophageal carcinoma cell lines, 
likely through reduction of cyclin D1 and upregulation 
of p27 (Hong et al., 2010). 
Gastric cancers 
Note 
miR-296-5p overexpression significantly promoted 
gastric cancer cells growth through repression of 
Caudal-related homeobox 1 (CDX1), an intestinal-
specific transcription factor, reported to have vital roles 
in gastric intestinal metaplasia (Li et al., 2013). 
Colon cancers 
Note 
Decrease in miR-296 circulating levels, in patients with 
colon cancer, predicts chemotherapy resistance and is 
associated with metastasis formation. Low levels of 
circulating miR-296 in patients with colon cancers 
reflect more aggressive tumor phenotype and increased 
tumor cell invasiveness (Shivapurkar et al., 2012). 
Immortalized cells 
Note 
In immortalized cells, miR-296 is frequently 
upregulated and the over-expression has been reported 
to determine p53 down-regulation. A number of cancer 
cells express high levels of miR-296, that 
downregulates p21WAF1 mRNA expression via 
interaction with its 3' untranslated region (Yoon et al., 
2011). 
Angiogenesis 
Note 
miR-296 was identified in endothelial cells of normal 
and neoplastic tissues, where it promoted angiogenesis 
through inhibition of one of its target gene, the 
hepatocyte growth factor-regulated tyrosine kinase 
substrate (HGS). HGS normally stimulates degradation 
of growth factors receptors, such as vascular 
endothelial receptor-2 (VEGFR2) and platelet derived 
growth factor receptor β (PDGFR-β) (Wurdinger et al., 
2008). 
Hypertension 
Note 
The human with-no-lysine kinase-4 (hWNK4) is a 
member of the serine-threonine protein kinase family 
and may be involved in pathophysiological processes 
of hypertension as it regulates diverse ion transporters. 
Expression of hWNK4 can be downregulated by miR-
296 at the posttranscriptional level in a cell-specific 
manner (Mao et al., 2010). 
Anti-viral defences 
Note 
Human miR-296-5p inhibits enterovirus EV71 
replication by targeting the viral genome. miR-296 has 
a role as critical effectors in intricate networks of host-
pathogen: effectively miR-296-5p was found to be 
significantly increased in response to EV71 infection. 
Overexpression of miR296-5p inhibited EV71 infection 
(Zheng et al., 2013). 
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